The largest database of trusted experimental protocols

17 protocols using cyclophosphamide ctx

1

Orthotopic Breast Tumor Model in SCID Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols
To establish an orthotopic breast tumor model, we first purified RFP+ cells from passages 10–15 of Tri-PyMT cell culture by FACS. The purified RFP+ Tri-PyMT cells (1×106 cells with purity >99%, Extended Data Fig. 5a) were injected into the mammary fat pad of 8-week old female CB-17 SCID mice. The growth of the primary tumor was monitored by external caliper measurement once a week. In approximately 4 weeks, the primary tumor was surgically removed and the incision was closed with wound clips. The tumor size did not exceed 5% of total body weight as permitted in the IACUC protocol. Animals were sacrificed 4 weeks after primary tumor removal to analyze the development of pulmonary metastasis. For animals subjected to chemotherapy, Cyclophosphamide (CTX, Sigma-Aldrich, 100mg/kg) was administered once per week, for 2 weeks prior and 2 weeks after surgery.
+ Open protocol
+ Expand
2

Antibody characterization and in vivo use

Check if the same lab product or an alternative is used in the 5 most similar protocols
The 314.8 mAb (mouse IgG1 anti-human ICOS) has been described before.21 Isotype controls (mouse IgG1, MOPC-1; rat IgG2b, LTF-2) and anti-Gr1 mAb (rat IgG2b, RB6-8C5) were purchased from BioXcell (West Lebanon, NH, USA). The MT807R1 recombinant Ig consisting of rhesus IgG1k constant regions and CDRs derived from the anti-human CD8 antibody M-T807 grafted into rhesus variable framework regions and was provided by the Nonhuman Primate Reagent Resource (NIH contract HHSN272200900037C and grant RR016001). The antibody was expressed in vitro using serum-free medium and purified by protein-A affinity chromatography. Endotoxin was <1EU/mg. Cyclophosphamide (CTX, Sigma Aldrich) was prepared extemporaneously according to supplier technical data sheet, i.e to 20 mg/ml of injectable water. All reagents were injected intraperitoneally.
+ Open protocol
+ Expand
3

Cyclophosphamide Cytokine and Biomarker Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols
Cyclophosphamide (CTX), used as the positive drug, was purchased from Sigma (St. Lousis, MO, USA. Detecting kits for IL-2, TNF-α, VEGF, AST, ALT, CRE and BUN were purchased from Nanjing Jiancheng Biotechnology Co. (Nanjing, China).
+ Open protocol
+ Expand
4

Preparing Immunotherapy Reagents

Check if the same lab product or an alternative is used in the 5 most similar protocols
Anti-CD16/CD32, and FITC-, PE-, or cychrome-conjugated monoclonal antibodies (mAb) against Ly5.1, and anti-CD8 were purchased from BD Pharmingen (San Diego, CA). G-CSF (Neupogen) was purchased from the local pharmacy at the Medical University of South Carolina. Human gp10025–33 epitope (KVPRNQDWL: gp10025–33) (American Peptide Company, Sunny-vale, CA) was dissolved in 10% DMSO (Sigma, St. Louis, MO) and diluted in PBS (phosphate-buffered saline, pH 7.4). Cyclophosphamide (CTX; Sigma) and TLR3 agonist poly(I:C) (Invitrogen, Carlsbad, CA) were each re-constituted in PBS and frozen until use.
+ Open protocol
+ Expand
5

Cyclophosphamide-Induced Rat Model

Check if the same lab product or an alternative is used in the 5 most similar protocols
Male Sprague-Dawley (SD) rats, age 6–8 weeks, and weighing 250–300 g (Laboratory Animal Center of Guangxi Medical University, Guangxi, China) were acclimated for 5–7 days prior to use in an environment with controlled temperature and relative humidity, and a 12-h light-dark cycle. All animal studies and experimental protocols were approved by the Guangxi Medical University Institutional Animal Care and Use Committee. Cyclophosphamide (CTX) was purchased from Sigma (St. Louis, MO, USA).
+ Open protocol
+ Expand
6

Murine Cancer Cell Culture and Treatments

Check if the same lab product or an alternative is used in the 5 most similar protocols
The EG.7-OVA thymoma (ATCC® CRL-2113™), MCA205 fibrosarcoma cells and MCA205-Tlr3−/− obtained from mice lacking Tlr-3 (kindly provided by Zitvogel, Gustave Roussy Cancer Campus, Villejuif, France), were cultured in RPMI 1640 supplemented with 10% heat-inactivated fetal bovine serum (FBS, Lonza), 2 mM L-Glutamine (Lonza), 0.1 U/mL penicillin, 0.1 mg/mL streptomycin (Lonza), 10 mM HEPES, 1.0 mM sodium pyruvate (NaPir), and 0.05 mM β-mercaptoethanol (β-ME) (all from Lonza), hereafter referred to as complete RPMI, and split every three days. Gentamicin (G-418 sulphate, Gibco, 0.4 mg/mL) was added to EG.7-OVA at every medium change. The cell lines were routinely tested for the absence of mycoplasma and passaged for no more than four times from thawing. Cyclophosphamide (CTX, Sigma–Aldrich, St. Louis, MO, USA), the in vitro active analogue of CTX mafosfamide (4-thioethane sulfonic acid salt of 4-hydroxy-cyclophosphamide, MAFO, Sigma) and cisplatin (cis-diamminedichloroplatinum (II), CDDP, Sigma) were dissolved in saline and filtered sterile before use. Type I Interferon (IFN-I) was produced at the department of Oncology and Molecular Medicine as previously described [16 (link)]. A mock preparation was used as specificity control.
+ Open protocol
+ Expand
7

In Vitro Cytotoxicity Assay for A375 Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
Human MM cell line A375 was obtained from ATCC (Manassas, U.S.A.). 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) was purchased from Promega (Madison, U.S.A.). Dulbecco’s Modified Eagle’s Medium (DMEM) and fetal bovine serum (FBS) were obtained from Gibco (Waltham, USA). Cyclophosphamide (CTX) was purchased from Sigma (St. Louis, U.S.A.).
+ Open protocol
+ Expand
8

Orthotopic Breast Tumor Model in SCID Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols
To establish an orthotopic breast tumor model, we first purified RFP+ cells from passages 10–15 of Tri-PyMT cell culture by FACS. The purified RFP+ Tri-PyMT cells (1×106 cells with purity >99%, Extended Data Fig. 5a) were injected into the mammary fat pad of 8-week old female CB-17 SCID mice. The growth of the primary tumor was monitored by external caliper measurement once a week. In approximately 4 weeks, the primary tumor was surgically removed and the incision was closed with wound clips. The tumor size did not exceed 5% of total body weight as permitted in the IACUC protocol. Animals were sacrificed 4 weeks after primary tumor removal to analyze the development of pulmonary metastasis. For animals subjected to chemotherapy, Cyclophosphamide (CTX, Sigma-Aldrich, 100mg/kg) was administered once per week, for 2 weeks prior and 2 weeks after surgery.
+ Open protocol
+ Expand
9

Cytotoxic Effects of Dispersant Corexit

Check if the same lab product or an alternative is used in the 5 most similar protocols
Cisplatin (CDDP) and cyclophosphamide (CTX) were obtained from Sigma-Aldrich (St. Louis, MO) and used at final concentrations of 0.2, 1, and 5 μM. Nalbuphine was obtained from the NIH Clinical Collection (South San Francisco, CA) and used at final concentrations of 0.2, 1, and 5 μM. Nalbuphine was selected as a negative control based on its known in vivo injection strength at doses of 20 mg/ml (approximately 70 μM) (FDA, 2014 ). Corexit EC 9500A (CE) was obtained via a Material Transfer Agreement from Nalco (Sugar Land, Texas). CE was used at final concentrations of 5, 10, 25, 50, 75, 100, 125, 150, 200, 250, 300, 350 and 400 ppm, which correspond to 4.75, 9.5, 23.75, 47.5, 71.25, 95, 118.75, 142.5, 180, 237.5, 285, 332.5, and 380 mg/L. The doses of CE were chosen based on data from evaluation of differential cytotoxic effects of the oil spill dispersant Corexit 9500 (Zheng et al., 2014 (link)). The LC50 values for Corexit were 16 ppm in BL16/BL6 cells, 33 ppm in 1321N1 cells, 70 ppm in H19-7 cells, 93 ppm in HEK293 cells, and 95 ppm in HK-2 cells (Zheng et al., 2014 (link)).
+ Open protocol
+ Expand
10

Fisetin-Mediated Immunomodulation Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols
Fisetin (>98% pure, catalog number: 528483, Figure 1) was obtained from Sigma-Aldrich and diluted in culture media containing 0.1% DMSO, sterile filtered, and stored at 4°C prior to utilization. An equivalent DMSO concentration was used for all control animals. Cyclophosphamide (CTX) and 2,4-dinitrofluorobenzene (DNFB) were procured from Sigma (MO, USA). RPMI-1640 was from HyClone (Logan, UT). Moreover, BioLegend (CA, USA) supplied IL-6, IL-17, TGF-β, TNF-α, and IL-10 ELISA kits. PE-anti-IL-17A, FITC-anti-CD4, APC-anti-CD25, and PE-anti-Foxp3 were from BD Pharmingen.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!